Taken together, these studies suggest that ELISspot may have a superior prognostic power as a biomarker for fetal infection risk, possibly because it assesses both CD4+ and CD8+ T-cell responses, unlike the IGRA test, which targets only CD8+ responses [53]. This evidence concerns the gene CD8A and infection.